New drug HuL001 takes first step in human trials for lung scarring disease
NCT ID NCT04540770
First seen Sep 30, 2025 · Last updated May 18, 2026 · Updated 35 times
Summary
This early-stage study tested a new drug called HuL001 in 24 people, including healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. The main goal was to check if the drug is safe and how the body processes it. Researchers monitored side effects and lab results to determine tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mackay Memorial Hospital
New Taipei City, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.